MedTrace Logo

Folinic Acid in Children With Autism Spectrum Disorders

NCT02551380 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-04-07

No results posted yet for this study

Summary

The investigator planned to study the efficiency of folinic acid treatment on autistic symptoms in children suffering from autism spectrum disorder.

Conditions

Interventions

DRUG

FOLINORAL

Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks

OTHER

Placebo

Placebo 5mg twice a day (10 mg per day) during 12 weeks

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Bruno Leheup, M.D, Ph.D · CHU NANCY- Hopital Brabois Enfants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02551380 on ClinicalTrials.gov